

- 1165-1169, 2009.
- 23) Douillard JY, et al. : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer : a multicentre randomised trial. *Lancet*, 355 : 1041-1047, 2000. Erratum in : *Lancet*, 355 : 1372, 2000.
- 24) Tournigand C, et al. : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study. *J Clin Oncol*, 22 : 229-237, 2004.
- 25) Noda K, et al. : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer : *N Eng J Med*, 346 : 85-91, 2002.
- 26) Masuda N, et al. : CPT-11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol*, 10 : 1225-1229, 1992.
- 27) Negoro S, et al. : CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. *Br J Cancer*, 88 : 335-341, 2003.
- 28) Ohe Y, et al. : Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan. : *Ann Oncol*, 18 : 317-323, 2007.
- 29) Perez EA, et al. : Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. *J Clin Oncol*, 22 : 2849-2855, 2004.
- 30) Hoskins JM, et al. : UGT1A1 *28 genotype and irinotecan-induced neutropenia : dose matters. *J Natl Cancer Inst*, 99 : 1290-1295, 2007.

[北川智余恵, 坂 英雄]

